Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.

Mult Scler · 2022 · PMC9732786 · PMID 36131595

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

In AFFIRM, the differences in mean EDSS over 96 weeks and at Week 96 were both nominally significant in favor of natalizumab treatment versus placebo.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.